The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
New thrombopoietic growth factors
Open accessAbstract
Although development of first-generation thrombopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rHuMGDF]) was stopped due to development of antibodies to PEG-rHuMGDF, nonimmunogenic second-generation thrombopoietic growth factors with unique pharmacologic properties have been developed. TPO peptide mimetics contain TPO receptor-activating peptides inserted into complementarity-determining regions of Fab (Fab 59), attached to the IgG Fc region (AMG 531), or pegylated (Peg-TPOmp). Orally available, TPO nonpeptide mimetics (eltrombopag, AKR-501) bind and activate the TPO receptor by a mechanism different from TPO and may have an additive effect to TPO. TPO agonist antibodies are monoclonal antibodies activating the TPO receptor but modified in size [TPO minibodies; ie, VB22B sc(Fv)2] or immunoglobuln type (domain subclass-converted TPO agonist antibodies; ie, MA01G4G344). All second-generation thrombopoietic growth factors stimulate growth of TPO-dependent cell lines via JAK2/STAT signaling pathways and increase platelet counts in animals. When tested in healthy humans, TPO peptide and nonpeptide mimetics produced a dose-dependent rise in platelet count. AMG 531 and eltrombopag markedly increase platelet counts in patients with immune thrombocytopenic purpura, without significant adverse effects. One or more second-generation thrombopoietic growth factors should soon be clinically available for treating thrombocytopenic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
de Sauvage, F. J., Hass, P. E., Spencer, S. D., Malloy, B. E., Gurney, A. L., Spencer, S. A., Darbonne, W. C., Henzel, W. J., Wong, S. C., Kuang, W.-J., et al. (1994) · Nature · doi:10.1038/369533a0 · Cited by 1,263
Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
Lok, S., Kaushansky, K., Holly, R. D., Kuijper, J. L., Lofton-Day, C. E., Oort, P. J., Grant, F. J., Heipel, M. D., Burkhead, S. K., Kramer, J. M., et al. (1994) · Nature · doi:10.1038/369565a0 · Cited by 1,070
Bartley, T. (1994) · Cell · doi:10.1016/0092-8674(94)90450-2 · Cited by 940
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Self-citationErythropoietin Receptor Activation by a Ligand-Induced Conformation Change
Remy, I., Wilson, I. A., & Michnick, S. W. (1999) · Science · doi:10.1126/science.283.5404.990 · Cited by 634
Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor Before Ligand Activation
Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K., & Wilson, I. A. (1999) · Science · doi:10.1126/science.283.5404.987 · Cited by 599
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., Conklin, G. T., Lichtin, A. E., Lyons, R. M., Nieva, J., Wasser, J. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054626 · Cited by 530
Self-citationKuter, D. J., Beeler, D. L., & Rosenberg, R. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11104 · Cited by 436
Self-citationPeptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine
Cwirla, S. E., Balasubramanian, P., Duffin, D. J., Wagstrom, C. R., Gates, C. M., Singer, S. C., Davis, A. M., Tansik, R. L., Mattheakis, L. C., Boytos, C. M., et al. (1997) · Science · doi:10.1126/science.276.5319.1696 · Cited by 403
Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets
Fielder, P., Gurney, A., Stefanich, E., Marian, M., Moore, M., Carver-Moore, K., & de Sauvage, F. (1996) · Blood · doi:10.1182/blood.v87.6.2154.bloodjournal8762154 · Cited by 341
Cited by
Provan, D., Stasi, R., Newland, A. C., Blanchette, V. S., Bolton-Maggs, P., Bussel, J. B., Chong, B. H., Cines, D. B., Gernsheimer, T. B., Godeau, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225565 · Cited by 2,271
Self-citationHow were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Kuter, D. J., Bussel, J. B., Lyons, R. M., Pullarkat, V., Gernsheimer, T. B., Senecal, F. M., Aledort, L. M., George, J. N., Kessler, C. M., Sanz, M. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60203-2 · Cited by 867
Self-citationLu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Metadata
- Authors
- Kuter, D. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-06-01
- Volume
- 109
- Issue
- 11
- Pages
- 4607-4616
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4244215862
- Cited by
- 307
- References
- 46
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New thrombopoietic growth factors. https://app.cochat.ai/papers/10.1182/blood-2006-10-019315
- The paper
- Kuter, D. J. (2007). New thrombopoietic growth factors. Blood. https://doi.org/10.1182/blood-2006-10-019315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.